Phase I MiNivAn trial
| Study name | MiNivAn: Phase I study of I-131 MIBG, nivolumab and ch14.18/CHO |
| Study type | Phase I clinical trial |
| Principal investigator(s) | Dr Juliet Gray |
| Institutions | University Hospital Greifswald, University of Wisconsin, University of Southampton, University College London Hospital |
| Partners | Band of Parents, Harvey Hext Trust, J-A-C-K, Solving Kids’ Cancer US |
| Total awarded | $500,000 |
| Solving Kids’ Cancer UK contribution | £96,000 |
Overview
Relapse and refractory neuroblastoma remains a significant challenge, with few options available once a patient has exhausted the standard pathway.
The MiNivAn trial will explore new therapies that can be added in combination to standard anti-GD2 immunotherapy. It will test the combination of I-131 mIBG, an antibody called Nivolumab which promotes cell death, and standard anti-GD2 therapy. This will hopefully create an immunity to neuroblastoma, which is promising for relapsed patients as it works differently to specific chemotherapy drugs.
The ultimate aim is to reduce the number of spots of disease a child has so that they can continue on the standard treatment path to hopefully achieve remission.
Impact
Running this trial in the UK gives an option for families who are facing relapse, and with support from Solving Kids' Cancer UK it is more financially viable than trials abroad. If successful this treatment could move forward to a Phase II and III trial before introduction to the clinic as standard therapy.
